Since Pirfenidone is metabolised throughout the CYP1A2 enzyme pathway, any drug which inhibits this enzyme is probably going to precipitate the toxicity of pirfenidone: concomitant therapy is usually to be prevented. Extra checking and dosage adjustment may very well be desired in accordance with products labeling of CYP1A2 substrates. This https://bapta-am66542.blog5.net/71806481/v-9302-for-dummies